Jiankui He, who sparked controversy in 2018 with the announcement that he had used gene-editing technology on human embryos, has been sentenced to prison and fined, Chinese state media reported. His former professor at Rice University remains under investigation by the school.
The company, officially launched in 2018 after operating in stealth mode for a year, is developing technologies to enable genome editing at the single-letter level, as opposed to the "cutting" of DNA and RNA normally used in CRISPR/Cas9.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Researchers using CRISPR-Cas9 gene editing on cancer cell lines found that even when certain drugs' putative molecular targets were removed, they still killed the cancer cells, indicating their mechanisms were not understood.
One of the four sites of the trial, in a rare form of inherited blindness, is currently listed as open for enrollment, and the companies plan to dose the first patient soon.
The company, partnered with Beam Therapeutics, Verily Life Sciences and academic institutions, plans to use gene editing to tackle coronary artery disease. However, experience with gene therapy indicates cost could be a hurdle.
The 18 signatories emphasized that the moratorium wouldn't constitute a ban or include gene editing for research or treatment of diseases, but called on nations to develop a framework to govern the practice.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
Shares of gene-editing companies were down Tuesday morning following the news, but analysts sought to reassure investors about Editas.
The company said it would use the funding to expand its single-cell DNA sequencing platform into CRISPR applications and global markets.
Tango Therapeutics - which uses CRISPR-based screening to find drug candidates - will receive $50 million upfront and be eligible for up to $1.7 billion in milestones, royalties and other payments.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The financing, led by Thiel's Founders Fund, will help the company expand its reach into Europe and Asia while building up its manufacturing capabilities.
The agency also accepted the two companies' IND to begin the Phase I/II study of CTX001 in patients with sickle cell disease, sending CRISPR shares up more than 11 percent Thursday morning.
The decision in favor of Broad Institute of MIT and Harvard by a panel of judges at the US Court of Appeals for the Federal Circuit leaves UC Berkeley with few options to appeal further.
Two papers in Nature have raised safety concerns about the gene-editing technology.
FDA slaps clinical hold on Crispr Therapeutics and Vertex Pharmaceuticals' upcoming gene-editing trial.